Skip to main content
SpringerLink
Log in

Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®)

Profile Report

  • Adis Profile Report
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Deeks ED. Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo®): in adults and adolescents. Biodrugs 2010; 24(5): 287–97

    Article  PubMed  CAS  Google Scholar 

  2. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseriameningitidis. Lancet 2007 Jun 30; 369(9580): 2196–210

    Article  PubMed  Google Scholar 

  3. Reisinger KS, Black S, Stoddard JJ. Optimizing protection against meningococcal disease. Clin Pediatr (Phila) 2010 Jun; 49(6): 586–97

    Article  Google Scholar 

  4. Hill DJ, Griffiths NJ, Borodina E, et al. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond) 2010 Feb 9; 118 (Pt 9): 547–64

    CAS  Google Scholar 

  5. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009 Jun 24; 27Suppl. 2: B51–63

    Article  PubMed  Google Scholar 

  6. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001 May 3; 344(18): 1378–88

    Article  PubMed  CAS  Google Scholar 

  7. Bröker M, Dull PM, Rappuoli R, et al. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009 Sep 18; 27(41): 5574–80

    Article  PubMed  Google Scholar 

  8. Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009 Dec; 16(12): 1810–5

    Article  PubMed  CAS  Google Scholar 

  9. Sanofi Pasteur Inc. Meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine Menactra®: US prescribing information [online]. Available from URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf [Accessed 2010 Apr 26]

  10. Sanofi Pasteur Inc. Menactra™ (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine): Canadian prescribing information [online]. Available from URL: http://www.menactra.ca/UserFiles/File/Menactra_HCP_EN.pdf [Accessed 2010 Apr 26]

  11. Advisory Committee on Immunization Practices. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2–10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep 2008 May 2; 57(17): 462–5

    Google Scholar 

  12. Novartis Vaccines and Diagnostics Inc. Menveo® (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) solution for intramuscular injection: US prescribing information [online]. Available from URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf [Accessed 2010 Apr 16]

  13. Novartis Vaccines. Menveo group A, C, W135 and Y conjugate vaccine: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 Apr 20]

  14. Advisory Committee on Immunization Practices. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010 Mar 12; 59(9): 273

    Google Scholar 

  15. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009 Feb; 28(2): 86–91

    Article  PubMed  Google Scholar 

  16. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009 Jul; 1; 49(1): e1–10

    Article  PubMed  Google Scholar 

  17. Stamboulian D, Lopardo G, Lopez P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. Epub 2010 Jul 21

    Google Scholar 

  18. Gill C, Kleinschmidt A, Anemona A, et al. Antibody persistence 22 months after vaccination of adolescents with the Menveo™ conjugate vaccine or Menactra®. Poster presented at the 14th International Congress on Infectious Diseases; 2010 Mar 9–12; Miami (FL)

  19. Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010 Apr; 17(4): 537–44

    Article  PubMed  CAS  Google Scholar 

  20. Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28(18): 3171–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments and Disclosures

The full text article[1] from which this profile report was derived was reviewed by: R. Gasparini, Department of Health Sciences, Genoa University, Genoa, Italy; D. Pace, Department of Paediatrics, Mater Dei Hospital, Msida, Malta. The manufacturer of the agent under review was offered an opportunity to comment on the original article[1] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit. The preparation of the original article and the profile report was not supported by any external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Additional information

Adapted and reproduced from the original article published in BioDrugs 2010; 24 (5): 287–97.[1]

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deeks, E.D. Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®). Pediatr Drugs 14, 63–65 (2012). https://doi.org/10.2165/11206930-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11206930-000000000-00000

Keywords

Search

Navigation